title: Anti-IgE therapy for allergic bronchopulmonary aspergillosis.
abstract: Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma. Some cases are resistant to treatment, even with regular use of antiasthmatic drugs and antifungal agents. The diagnosis of ABPA was made in a 40-year-old patient with ABPA according to the Rosenberg-Patterson criteria. Symptoms were not controlled despite regular use of antiasthmatic drugs, daily systemic steroids, and antifungal agents. Omalizumab, administered in an attempt to stabilize these uncontrolled symptoms, was effective with no adverse events. Our experience suggests omalizumab is a potential candidate drug for controlling steroid-dependent ABPA.
authors.affiliation: Division of Allergology and Respiratory Medicine, Division of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan. Electronic address: oldham726@yahoo.co.jp.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Homma
authors.affiliation: Division of Allergology and Respiratory Medicine, Division of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Kurokawa
authors.affiliation: Division of Allergology and Respiratory Medicine, Division of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Matsukura
authors.affiliation: Division of Allergology and Respiratory Medicine, Division of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.
authors.forename: Munehiro
authors.initials: M
authors.lastname: Yamaguchi
authors.affiliation: Division of Allergology and Respiratory Medicine, Division of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Adachi
mesh_terms: D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000187:drug effects / Q000276:immunology; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000935:Antifungal Agents; C026408:anti-IgE antibodies; D000069444:Omalizumab
keywords: Allergic bronchopulmonary aspergillosis; IgE; Omalizumab; Prednisolone; Severe asthma